史雨晨,柳景华

• 1:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所

摘要(Abstract)：

<正>急性冠状动脉综合征(acute coronary syndrome,ACS)是冠状动脉粥样硬化性心脏病(冠心病)中的危重临床类型,其主要包括不稳定型心绞痛、非ST段抬高型心肌梗死和ST段抬高型心肌梗死[1]。近年来为更好地指导临床早期治疗方案,特别是心肌再灌注策略的制定,又将前两者合称为非ST段抬高型ACS(约占ACS的3/4),将后者称为ST段抬高型ACS(约占ACS的1/4)。ACS具有共同的病理生理机制,而又因心肌缺血程度、

关键词(KeyWords)： 成纤维细胞生长因子;急性冠状动脉综合征

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81570388);; 国家重点基础研究发展计划(973计划)课题(2015CB554404);; 北京市自然科学基金项目(7142048)

作者(Author): 史雨晨,柳景华

参考文献(References)：

• [1]杨丽霞,郭瑞威.《中国经皮冠状动脉介入治疗指南(2016)》指导急性冠状动脉综合征的临床实践.中国介入心脏病学杂志,2016,24(12):714-717.
• [2]AlpertJS. TheFourthEditionoftheUniversalDefinition of Myocardial Infarction. Am J Med,2018,131(11):1265-1266.
• [3]XieT, LeungPS. Fibroblastgrowthfactor21:aregulator of metabolic disease and health span. Am J Physiol Endocrinol Metab,2017,313(3):E292-E302.
• [4]Lee CH, Woo YC, Chow WS, et al. Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among chinese patients with type 2 diabetes mellitus. J Am Heart Assoc,2017,6(6):e5344.
• [5]Emmanuel S, Jornayvaz FR. Fibroblast growth factor 15/19-from basic functions to therapeutic perspectives. Endocr Rev,2018.[Epub ahead of print]
• [6]NishimuraT, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta,2000,1492(1):203-206.
• [7]Strowski MZ. Impact of FGF21 on glycemic control. Horm Mol Biol Clin Investig,2017,30(2).[Epub ahead of print]
• [8]Gómez-Sámano M?, Grajales-Gómez M, Zuarth-Vázquez JM, et al.Fibroblast growth factor 21 and its novel association with oxidative stress.Redox Biol,2017,11:335-341.
• [9]HansenA, VienbergSG, LykkegaardK, etal.Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in db/db mice.Biochem J,2018,475(18):2985-2996.
• [10]Huang Z, Xu A, Cheung BMY. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. Current Hypertension Reports,2017,19(4):28.
• [11]Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol(Oxf),2014,80(1):57-64.
• [12]史雨晨,柳景华.成纤维细胞生长因子21在大鼠各组织中表达分布的研究.心肺血管病杂志,2016,35(07):574-577.
• [13]Kokkinos J, Tang S, Rye KA, et al. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis,2017,257:259-265.
• [14]Cheng P, Zhang F, Yu L, et al. Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res,2016,2016:1540267.
• [15]YusufS, HawkenS, OunpuuS, etal.Effect of potentially modifiable risk factors associated with myocardial infarction in 52countries(the INTERHEART study):case-control study. Lancet,2004,364(9438):937-952.
• [16]ZhangW, ChuS, Ding W, et al. Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One,2015,10(6):e129791.
• [17]曲军. STEMI患者血清FGF21在急诊PCI前后的动态变化及其与心功能相关性的临床研究.青岛大学,2015.
• [18]KondoH, HojoY, SaitoT, etal. Relationshipbetween fibroblast growth factor 21 and extent of left ventricular remodeling after acute myocardial infarction. J Clinic Experimental Cardiol,2011,2(6):1-6.
• [19]Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun,2015,459(1):124-130.
• [20]Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue.Sci Rep,2013,3:2767.
• [21]Hu S, Cao S, Liu J. Role of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusioninduced injury in H9c2 cardiomyocytes. Exp Ther Med,2017,14(1):771-779.
• [22]朱慧.成纤维细胞生长因子21对心脏血管内皮细胞的保护作用.首都医科大学,2013.
• [23]Soler-Vázquez MC, Mera P, Zagmutt S, et al. New approaches targeting brown adipose tissue transplantation as a therapy in obesity.Biochem Pharmacol,2018,155:346-355.
• [24]RupérezC,LerinC,Ferrer-CurriuG, etal.Autophagic control of cardiac steatosis through FGF21 in obesity-associated cardiomyopathy. Int J Cardiol,2018,260:163-170.
• [25]Tanajak P, Chattipakorn SC, Chattipakorn N. Effects of fibroblast growth factor 21 on the heart. J Endocrinol,2015,227(2):R13-R30.
• [26]Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update:a report from the American Heart Association. Circulation,2018,137(12):e67-e492.